In the high-stakes world of AI drug discovery, most startups are drowning in hype. Auransa is quietly moving into Phase 1 clinical trials. With a team of just 15 people and a biology-first approach, they aren't just building algorithms—they're building drugs.

"Auransa isn't just predicting molecules; they are validating them in human trials. That's the difference between a tech demo and a biopharma."

The traffic data reveals a company in stealth mode rather than marketing overdrive. With only 19 monthly visits and a global rank that is effectively unlisted, Auransa is operating under the radar. This isn't a consumer-facing AI tool; it's a deep-tech machine focused on regulatory approvals and scientific validation, not SEO dominance.

• Clinical Stage Reality: Moving beyond algorithms into actual human trials (AU409).
• Lean Operations: Achieving clinical milestones with a team of 15 and $2.8M revenue.
• Niche Focus: Targeting liver cancer with a proprietary AI platform designed for complex diseases.